01 April 2016

Gilead Statement on the Approval of PrEP in Peru

Gilead Sciences, Inc. is pleased to share that the Peru Ministry of Health has approved the use of once-daily oral Truvada® (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) as pre-exposure prophylaxis (PrEP), in combination with safer sex practices, to help reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk.

Gilead believes that Truvada for PrEP is an important HIV prevention tool that, when taken as directed and used in combination with other prevention strategies, has demonstrated the potential to help reduce new HIV infections. It is supported by guidelines from the World Health Organization and the U.S. Centers for Disease Control as part of a comprehensive HIV prevention strategy among high-risk populations.

For information on the safety profile and appropriate use of Truvada for PrEP, please see the full prescribing information.

Gilead, together with its regional business partner in Peru, Gador S.A., will work with the local HIV community on educational efforts to support the safe and appropriate use of PrEP.

Truvada for PrEP was approved in the United States in July 2012, in Kenya and South Africa in December 2015, and in Canada in February 2016. The French regulatory agency (ANSM) also has approved the temporary use of PrEP (RTU). Additionally, the European Medicines Agency is currently assessing a PrEP marketing authorization for all 28 member states of the European Union, Norway and Iceland. Other regulatory filings are pending in Australia, Brazil and Thailand.